您现在的位置: 首页> 研究主题> PGE1

PGE1

PGE1的相关文献在1989年到2022年内共计179篇,主要集中在内科学、外科学、药学 等领域,其中期刊论文146篇、会议论文2篇、专利文献31篇;相关期刊115种,包括中华实用中西医杂志、中国应用生理学杂志、现代诊断与治疗等; 相关会议2种,包括第九次全国整形外科学术会议、第二次全国中西医结合男科学术会议等;PGE1的相关文献由452位作者贡献,包括伊莎贝尔·利奥蒂尔、等、奥利维尔·康明比欧夫等。

PGE1—发文量

期刊论文>

论文:146 占比:81.56%

会议论文>

论文:2 占比:1.12%

专利文献>

论文:31 占比:17.32%

总计:179篇

PGE1—发文趋势图

PGE1

-研究学者

  • 伊莎贝尔·利奥蒂尔
  • 奥利维尔·康明比欧夫
  • 杨永录
  • 海因茨·弗雷兹
  • 王鹏
  • 蒂诶里·西弗朗
  • 西尔维娅·理查德-比尔德斯滕
  • 赫尔夫·斯恩德特
  • 达维德·波齐
  • 期刊论文
  • 会议论文
  • 专利文献

搜索

排序:

年份

    • 马铭婕; 许琪
    • 摘要: 目的 研究在抑郁症(MDD)患者队列外周血及慢性不可预知温和型应激(CUMS)小鼠模型大脑组织中前列腺素E1(PGE1)浓度及其代谢通路上的关键基因(PLA2、PTGS1、PTGS2和PTGES)表达量的改变,以明确PGE1的改变与MDD疾病间的关系.方法 用高效液相色谱(HPLC)检测受试者外周血浆和CUMS小鼠脑组织中PGE1和PGE2的浓度;用RT-qPCR检测PLA2、PTGS1、PTGS2和PTGES的mRNA表达水平.结果 在MDD患者中,血浆PGE1浓度和PTGS1的表达水平均显著上升(P<0.05).这一结果在CUMS小鼠外周血和大脑杏仁核组织中得到了有效验证.结论 PGE1在MDD中的上升,可能与前列腺素合成通路的功能亢进有关.
    • 佟雷; 高月娟; 孙延斌; 刘世娟; 刘金丽
    • 摘要: 目的:构建大鼠糖尿病肾病模型,对比氯沙坦联合前列腺素E1与单独使用氯沙坦及前列腺素E1对DN模型大鼠肾脏组织改变的差异.方法:大鼠静脉注射链脲佐菌素联合食物诱导糖尿病肾病大鼠模型,按照其给药方式分为六组,分别是空白组、模型对照组、氯沙坦组、前列腺素E1组、联合用药组,造模成功后连续用药4周,观察其血清尿素氮(BUN)、血清肌酐(Scr)、尿肌酐(Cr)及尿蛋白含量的变化.结果:联合用药组较模型组与单独给药组血清尿素氮(BUN)、血清肌酐(Scr)、尿肌酐(Cr)及尿蛋白含量都有明显变化(P<0.01或P<0.05).结论:氯沙坦与前列腺素E1联合应用对早期糖尿病肾病的治疗,较单独使用药效显著,此种给药方式对糖尿病肾病的临床治疗有重要的意义.
    • 胡宁; 王卫平
    • 摘要: 目的 观察前列地尔(PGE1)联合高频振荡通气(HFOV)在新生儿持续肺动脉高压(PPHN)中的应用价值.方法 按随机数表法将2015年3月~2017年3月收治的98例PPHN患儿分为观察组和对照组各49例.对照组行HFOV治疗,观察组在对照组基础上给予PGE1治疗,持续3d.比较两组治疗前及治疗3d后血气分析指标、动脉血二氧化碳分压(PaCO2)]、肺动脉收缩压(SPAP)及体循环收缩压(SBP)差异,于治疗3d后评估两组疗效.结果 治疗3d后,两组pH、PaO2较治疗前显著上升,PaCO2、SPAP则较治疗前显著降低,且观察组变化幅度大于对照组(P均0.05).观察组总有效率显著高于对照组(P<0.05).结论 PGE1联合HFOV治疗PPHN对提高疗效、改善肺动脉高压和缺氧症状有一定帮助,于患儿病情转归有利.
    • Pratibha Devabhaktuni; M. G. S. Nagasree
    • 摘要: OBJECTIVES: In the very high risk obstetric cases of placental abruption, expediting delivery is of utmost urgency, since the complications are related to the abruption delivery interval. Before the introduction of prostaglandins for labor induction, it was a routine practice to do amniotomy and use oxytocin drip to accelerate labor when vaginal delivery was contemplated. We present 116 cases of placental abruption, including the severe cases, managed in the year 2006 during a period of 8 months, at Modern Government Maternity Hospital, which was the biggest maternity hospital in the combined state of Andhra Pradesh, and is the biggest in the state of Telangana, attached to Osmania Medical College. The role of prostaglandin E1 (PGE1), for cervical ripening and labor induction/augmentation has been analyzed in this observational study. A variety of variables including age, parity, gestational age, severity of abruption and maternal and fetal status, associated preeclampsia, Bishop score, availability of blood and blood products, associated complications, all factors influence the management adopted. MATERIAL METHODS: The response to PGE1 induction has been studied in terms of efficacy, the total number of doses of vaginal PGE1 in relation to parity, induction delivery interval, successful vaginal delivery rate, the indications for caesarean delivery, perinatal outcome and complications. A decision was made for either abdominal delivery or vaginal delivery on a case to case basis. A routine amniotomy was performed when the cervical os was open, both for confirmation of diagnosis and to release intra uterine pressure, and also it would help in the acceleration of labor. When the Bishop score was more than six, amniotomy was performed and an oxytocin intravenous drip was started. If the Bishop score was less than six, 25/50 mcg. Misoprostol (PGE1) was placed high in the vagina. OBSERVATIONS: Primies that had abruption were 27/116 = 23.27% and multies were 89/116 = 76.72%. In our study 68/116, (58.62%) had preeclamsia. In our series, gestational age at abruption was less than 36 weeks in 89/116, (76.72%) and >36 weeks in 27/116 (23.27%) at presentation. It is significant to note that 100/116 (86.2%) were unbooked and 16/116 (13.79%) were booked cases at our institute. Vaginal deliveries were 84 (74.2%) and caesarean deliveries were 30 (25.8%) in 116 placental abruptions. There were four maternal deaths 3.4%, two died undelivered. Perinatal mortality in our series was 92/116 (79.3%). PGE1 induced labours—49: When PGE1 was used for labor induction in 49 women, 40 (81.63%) had vaginal delivery and caesarean delivery was done in 9 (18.36%) cases for non progress of labor. Induction delivery interval was less than 12 hours in 45 (91.83%), more than 12 hours in 4 (8.1%). Preterm delivery in PGE1 induced cases was 40/49 = 81.63% versus preterm in 116 cases, 76.72%. This indicates that more numbers of preterm deliveries were allowed vaginal delivery. DISCUSSION: Maternal mortality: Better facilities of transfusion of blood products may have reduced maternal mortality in our series. Government maternity hospital is a public sector tertiary health facility providing free treatment. Early referral would make some difference. Acute defibrination leading to disseminated intravascular cougulation was the cause of three deaths, irreversible haemorrhagic shock in another. CONCLUSION: Induction of labor with PGE1 was useful and effective when cervix was unfavorable and Bishop score was less than six. With PGE1 induction (49) 91.83% delivered in less than 12 hours. There were no maternal deaths and PPH in 49 women induced with PGE1. Hence PGE1 was safe to use in these emergency high-risk obstetric patients. PGE1 usage to expedite delivery can reduce Caesarean section rate.
    • 宋威蓉; 赵华; 刘昌
    • 摘要: 目的:探讨雾化吸入前列腺素E1(PGE1)治疗支气管哮喘急性发作期对血气分析水平的影响.方法:选取本院2015年1-12月的50例支气管哮喘急性发作期患者为研究对象,将50例支气管哮喘急性发作期患者随机分为两组,其中对照组24例患者全身应用解痉、平喘、抗感染等常规综合治疗,治疗组26例患者在常规综合治疗的基础上加用雾化吸入PGE1治疗,并比较两组治疗3 d后患者的桡动脉血检测PaO2、PaCO2指标的变化.结果:治疗组患者经过治疗后总有效率为96.15%,明显高于对照组的67.67%,差异有统计学意义(P<0.05).治疗后,治疗组的PaO2、PaCO2均明显优于对照组,差异均有统计学意义(P<0.05).结论:加用雾化吸入PGE1治疗支气管哮喘急性发作期临床效果显著,大大的减少了患者的痛苦,提高了患者的生活质量,值得在临床中推广应用.
    • 全勇辉; 余守强; 周志良; 汪勇; 孙宝林
    • 摘要: 目的通过脏测血浆D二聚体(D—dimer)和超敏C反应蛋白水平(hs—CRP)变化来间接观察PGE1对肋骨骨折患者纤溶系统与全身性炎症反应的影响。方法对照组(A组)20例常规治疗。观察组(B维)26例在常规治疗基础上T1时点静脉注射前列地尔10μg.qd.7~10d。检测患者T0-T3的D-dimer或hs—CRP水平。结果两组D—dimer水平均在T0时点牡著增高,在T1~T3时点均明媪下降。A、B两组hs—CRP均在T1时点均达高峰,其前后备时点均处于较低水平。两因素蓖复测皱多元方差分析表明,各时点差异有统计学差异,P〈0.05;而各时点与组刚交互作用刚,差异无统计学差异,P〉0.05。结论在肋骨骨折患者中PGE1对血浆D-DIMER和hs—CRP水平无明娃影响。肋骨骨折患者纤溶系统在患者人院时即发生明显变化。而全身性炎症反应在24~48小时点明娃。
    • 王书军
    • 摘要: 目的:探讨PGE1治疗糖尿病末梢神经炎的临床疗效。方法选取2013年8月—2014年8月期间在我院住院治疗的糖尿病末梢神经炎患者70例,随机分为治疗组35例与对照组35例,分别给予不同的治疗措施,对两组患者的疗程治疗效果进行对比分析。结果两组患者治疗后的MCV改善情况较治疗前有好转,同组之间差异有统计学意义(P<0.05),治疗组患者治疗后的MCV改善程度高于对照组,两组之间差异有统计学意义(P<0.05)。治疗组患者的临床总有效率优于对照组,两组之间差异有统计学意义(P<0.05)。结论采用PGE1方法治疗糖尿病末梢神经炎具有良好的治疗效果,安全性高,值得在临床治疗中应用。
    • 罗晓强
    • 摘要: 目的:探究前列腺素E1 应用于肝硬化治疗的有效性.方法:选择88 例诊断明确的肝硬化患者为对象,收集其病例资料并进行回顾性分析,按治疗过程中是否使用前列腺素E1 分为研究组与对照组,以1 个月为观察期,比较两组治疗效果.结果:两组患者1 个月后肝功能各指标均有恢复,但研究组恢复更好,治疗总有效率对照组较研究组低,差异有统计学意义(P <0.05 ).结论:前列腺素E1 对肝硬化患者有一定的疗效,在改善患者肝功能、提高治疗效果等方面具有肯定意义.
    • 罗晓强
    • 摘要: 目的:探究前列腺素E1应用于肝硬化治疗的有效性。方法:选择88例诊断明确的肝硬化患者为对象,收集其病例资料并进行回顾性分析,按治疗过程中是否使用前列腺素E1分为研究组与对照组,以1个月为观察期,比较两组治疗效果。结果:两组患者1个月后肝功能各指标均有恢复,但研究组恢复更好,治疗总有效率对照组较研究组低,差异有统计学意义(P〈0.05)。结论:前列腺素E1对肝硬化患者有一定的疗效,在改善患者肝功能、提高治疗效果等方面具有肯定意义。
    • Shahla Siddiqui; Nawal Salahuddin; Salwa Zubair; Muniza Yousuf; Iqbal Azam; Anwarul Hassan Gilani
    • 摘要: Introduction: We wished to see the effects of inhaled PGE1 on diastolic dysfunction, left ventricular end diastolic pressure (LVEDP), pulmonary hypertension and hypoxia in ARDS patients. Methods: This is a randomized, prospective, clinical trial conducted in the main adult intensive care unit of a tertiary care University hospital. A total of 67 patients were recruited. Inclusion criteria included all adult patients with a P/F ratio 35 mmHg on Pulmonary artery catheter or suspected on clinical grounds. A transthoracic echo was performed to record the diastolic function, LVEDP and Pa pressures. Subsequently patients were randomized by a block computerized randomization to either cases (n = 34) or controls (n = 33). Cases received nebulised PGE1 over 30 minutes in the ICU and normal saline was administered to controls blindly. Following this the echo and arterial blood gases were repeated. Our primary outcomes were an improvement in diastolic function and P/F ratio of greater than 20% and a decrease in pulmonary pressure and LVEDP of >20%. Results: At baseline, mean diastolic dysfunction was grade II, with a mean LVEDP of >15 and the PaO2/FiO2 ratio was 148.38 ± 60.05 with a mean pulmonary artery pressure of 81.35 ± 16.91. Inhaled PGE1 was followed by an improvement in diastolic dysfunction (grade I, p = 0.001) with a resulting improvement in LVEDP (12 +/? 2, p = 0.001) as well as Pa pressures (97.09 ± 30.06, p = 0.04) and a non significant improvement in PaO2/FiO2 ratio (161.45 ± 77.52, p = 0.21). There were no side effects observed in any patients. Conclusion: Our study shows that there is a significant improvement in diastolic dysfunction, LVEDP and Pa pressures after administration of nebulised PGE1, and an improvement although non-significant in hypoxia in ARDS patients. The trial was registered with Clinicaltrials.gov (NCT00314548) and funded by the Pakistan medical research council.
  • 查看更多

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号